See more : Asymchem Laboratories (Tianjin) Co., Ltd. (6821.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Vaishali Pharma Limited (VAISHALI.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vaishali Pharma Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- TherapeuticsMD, Inc. (TXMD) Income Statement Analysis – Financial Results
- TTFB Company Limited (2729.TWO) Income Statement Analysis – Financial Results
- Norwegian Cruise Line Holdings Ltd. (0UC3.L) Income Statement Analysis – Financial Results
- MERLIN Properties SOCIMI, S.A. (MRL.MC) Income Statement Analysis – Financial Results
- Nomura System Corporation Co, Ltd. (3940.T) Income Statement Analysis – Financial Results
Vaishali Pharma Limited (VAISHALI.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.vaishalipharma.com
About Vaishali Pharma Limited
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers active pharmaceutical ingredients (APIs), including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The company also provides formulation products, such as antibiotics/antibacterial, anti-platelet, laxative, anti-ulcer/enzyme, anti-asthmatic, anti-malarial, anti-cold/anti-allergic/anti-viral, anti-psychotic, anti-fungal, anti-inflammatory/analgesic/anti-pyretic, anti-diabetic, cardiac, vitamins, topical steroids/corticosteroids, and other formulations. In addition, it offers veterinary pharmaceutical, nutraceutical, oncology, herbal, and surgical products. The company was founded in 1989 and is headquartered in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 862.80M | 696.63M | 715.37M | 523.08M | 584.11M | 724.56M | 654.98M | 660.55M | 667.07M | 945.61M | 1.21B | 1.19B |
| Cost of Revenue | 744.16M | 546.78M | 635.01M | 461.51M | 510.89M | 686.62M | 599.01M | 574.20M | 620.33M | 912.51M | 1.14B | 1.14B |
| Gross Profit | 118.64M | 149.85M | 80.36M | 61.56M | 73.22M | 37.94M | 55.97M | 86.35M | 46.74M | 33.10M | 64.87M | 52.59M |
| Gross Profit Ratio | 13.75% | 21.51% | 11.23% | 11.77% | 12.54% | 5.24% | 8.55% | 13.07% | 7.01% | 3.50% | 5.37% | 4.43% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.47M | 3.78M | 4.18M | 2.61M | 3.44M | 2.68M | 7.28M | 23.86M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 4.86M | 5.29M | 26.73M | 8.83M | 10.73M | 10.70M | 13.23M | 2.98M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 84.03M | 9.07M | 30.91M | 11.44M | 14.17M | 13.38M | 20.51M | 26.84M | 25.70M | 18.45M | 20.02M | 11.95M |
| Other Expenses | -4.66M | 22.29M | 473.43K | 1.52M | 12.76M | 96.35K | 17.53K | 10.57M | 31.84M | 42.63M | 8.61M | 2.89M |
| Operating Expenses | 84.03M | 63.60M | 16.07M | 21.14M | 26.93M | 20.04M | 28.99M | 55.57M | 44.94M | 40.51M | 40.58M | 37.23M |
| Cost & Expenses | 856.50M | 610.38M | 651.08M | 482.66M | 537.82M | 706.66M | 628.00M | 629.78M | 665.27M | 953.03M | 1.18B | 1.17B |
| Interest Income | 13.92M | 12.55M | 12.98M | 12.58M | 13.08M | 12.05M | 14.80M | 7.52M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 22.67M | 20.09M | 24.89M | 26.26M | 25.56M | 26.38M | 28.53M | 31.22M | 33.68M | 33.70M | 26.76M | 9.36M |
| Depreciation & Amortization | 5.08M | 5.04M | 4.56M | 4.27M | 4.38M | 2.69M | 2.55M | 2.78M | 3.67M | 4.53M | 441.00K | 343.00K |
| EBITDA | 31.71M | 113.59M | 86.44M | 44.42M | 29.99M | 40.40M | 44.53M | 44.09M | 37.32M | 39.74M | 33.34M | 18.58M |
| EBITDA Ratio | 3.68% | 16.30% | 12.12% | 12.00% | 12.40% | 5.54% | 6.80% | 6.64% | 5.59% | 4.20% | 2.76% | 1.56% |
| Operating Income | 6.29M | 88.74M | 64.29M | 22.21M | 4.63M | 17.89M | 26.98M | 30.77M | 1.80M | -7.42M | 24.29M | 15.36M |
| Operating Income Ratio | 0.73% | 12.74% | 8.99% | 4.25% | 0.79% | 2.47% | 4.12% | 4.66% | 0.27% | -0.78% | 2.01% | 1.29% |
| Total Other Income/Expenses | 2.97M | -1.26M | -7.48M | -8.17M | -45.50M | -6.80M | -11.94M | -21.63M | -1.84M | 8.94M | -18.15M | -6.47M |
| Income Before Tax | 9.26M | 88.45M | 57.28M | 14.05M | 791.05K | 11.32M | 13.45M | 10.13M | -36.00K | 1.52M | 6.14M | 8.89M |
| Income Before Tax Ratio | 1.07% | 12.70% | 8.01% | 2.69% | 0.14% | 1.56% | 2.05% | 1.53% | -0.01% | 0.16% | 0.51% | 0.75% |
| Income Tax Expense | 2.07M | 22.42M | 17.05M | 3.58M | 463.21K | 4.19M | 5.48M | 3.49M | 267.00K | -97.00K | 3.14M | 2.89M |
| Net Income | 7.19M | 66.04M | 40.24M | 10.46M | 327.84K | 7.14M | 7.98M | 6.64M | -303.00K | 1.62M | 3.01M | 6.00M |
| Net Income Ratio | 0.83% | 9.48% | 5.62% | 2.00% | 0.06% | 0.98% | 1.22% | 1.00% | -0.05% | 0.17% | 0.25% | 0.51% |
| EPS | 0.68 | 6.26 | 3.82 | 0.99 | 0.03 | 0.68 | 0.88 | 0.67 | -0.03 | 0.15 | 0.28 | 0.57 |
| EPS Diluted | 0.06 | 5.91 | 3.82 | 0.99 | 0.03 | 0.68 | 0.88 | 0.67 | -0.03 | 0.15 | 0.28 | 0.57 |
| Weighted Avg Shares Out | 10.62M | 11.17M | 10.55M | 10.55M | 10.55M | 10.55M | 9.05M | 10.55M | 10.55M | 10.55M | 10.55M | 10.55M |
| Weighted Avg Shares Out (Dil) | 112.33M | 11.17M | 10.55M | 10.55M | 10.55M | 10.55M | 9.05M | 10.55M | 10.55M | 10.55M | 10.55M | 10.55M |
Source: https://incomestatements.info
Category: Stock Reports